tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GOSS Stock Latest News

Gossamer Bio: PROSERA Phase 3 as a Nuanced, High‑Probability Catalyst Supporting Buy Rating and Defined Downside
RatingsGossamer Bio: PROSERA Phase 3 as a Nuanced, High‑Probability Catalyst Supporting Buy Rating and Defined Downside
4d ago
GOSS
Gossamer Bio files automatic mixed securities shelf
PremiumThe Fly
Gossamer Bio files automatic mixed securities shelf
16d ago
GOSS
Gossamer Bio initiated with an Overweight at Barclays
PremiumThe Fly
Gossamer Bio initiated with an Overweight at Barclays
17d ago
GOSS
Gossamer Bio: Seralutinib’s Phase 3 PROSERA Trial as a 2026 Value-Defining Catalyst Supporting Buy Rating and $10 Target
PremiumRatings
Gossamer Bio: Seralutinib’s Phase 3 PROSERA Trial as a 2026 Value-Defining Catalyst Supporting Buy Rating and $10 Target
23d ago
GOSS
Gossamer Bio management to meet with Oppenheimer
PremiumThe Fly
Gossamer Bio management to meet with Oppenheimer
2M ago
GOSS
Gossamer Bio’s Seralutinib Advances: Buy Rating Backed by Promising Late-Stage Trials and Expansion
PremiumRatingsGossamer Bio’s Seralutinib Advances: Buy Rating Backed by Promising Late-Stage Trials and Expansion
3M ago
GOSS
Gossamer Bio price target raised to $12 from $9 at Oppenheimer
Premium
The Fly
Gossamer Bio price target raised to $12 from $9 at Oppenheimer
3M ago
GOSS
Gossamer Bio Reports Q3 2025 Results and Updates
Premium
Company Announcements
Gossamer Bio Reports Q3 2025 Results and Updates
3M ago
GOSS
Gossamer Bio reports Q3 EPS (21c), consensus (20c)
PremiumThe Fly
Gossamer Bio reports Q3 EPS (21c), consensus (20c)
3M ago
GOSS
3 Best Stocks to Buy Now, 9/26/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 9/26/2025, According to Top Analysts
5M ago
DEFT
GOSS
Gossamer Bio Enters Merger Agreement with Respira
PremiumCompany Announcements
Gossamer Bio Enters Merger Agreement with Respira
5M ago
8K
GOSS
Gossamer Bio signs option to acquire Respira Therapeutics
PremiumThe Fly
Gossamer Bio signs option to acquire Respira Therapeutics
5M ago
GOSS
Gossamer Bio to acquire Respira Therapeutics in all-stock transaction
PremiumThe FlyGossamer Bio to acquire Respira Therapeutics in all-stock transaction
5M ago
GOSS
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
5M ago
BNC
NFE
Gossamer Bio’s Seralutinib: Promising Advancements in PAH Treatment Reinforce Buy Rating
Premium
Ratings
Gossamer Bio’s Seralutinib: Promising Advancements in PAH Treatment Reinforce Buy Rating
5M ago
GOSS
Cantor says has reinforced conviction on Gossamer Bio ahead of data readout
PremiumThe Fly
Cantor says has reinforced conviction on Gossamer Bio ahead of data readout
5M ago
GOSS
Gossamer Bio upgraded to Buy from Neutral at UBS
PremiumThe Fly
Gossamer Bio upgraded to Buy from Neutral at UBS
5M ago
GOSS
Gossamer Bio’s Seralutinib: Promising Long-Term Therapy with Upcoming Catalysts
PremiumRatings
Gossamer Bio’s Seralutinib: Promising Long-Term Therapy with Upcoming Catalysts
6M ago
GOSS
Gossamer Bio Reports Q2 2025 Financial Results
PremiumCompany Announcements
Gossamer Bio Reports Q2 2025 Financial Results
6M ago
GOSS
Gossamer Bio’s Promising Clinical Advancements and Strategic Positioning Earns Buy Rating
PremiumRatingsGossamer Bio’s Promising Clinical Advancements and Strategic Positioning Earns Buy Rating
6M ago
GOSS
Gossamer Bio reports Q2 EPS (17c) , consensus (18c)
Premium
The Fly
Gossamer Bio reports Q2 EPS (17c) , consensus (18c)
6M ago
GOSS
Gossamer Bio initiated with an Outperform at Scotiabank
Premium
The Fly
Gossamer Bio initiated with an Outperform at Scotiabank
7M ago
GOSS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >